Research peptides held in Australian stock, every lot tested by HPLC and mass spectrometry. For laboratory research use only.
Cart 0

MOTS-c Benefits: A Review of the Evidence Published to Date

The MOTS-c benefits described in the literature so far are all metabolic, and nearly all of it comes from mice. Treated animals resisted the weight gain and insulin resistance a high-fat diet normally causes, and they performed better physically at each age the researchers checked. Human evidence is thin. The single finished trial tested CB4211, an engineered analogue, and saw liver enzymes drop across four weeks. A phase 2a study of the native peptide is now enrolling, which means its effects and its risks in people remain largely unmeasured.

MOTS-c Explained in Brief

Spelled out, the acronym means mitochondrial open reading frame of the 12S rRNA type-c. Its sixteen residues run MRWQEMGYIFYPRKLR, and the code for them lives in mitochondrial DNA, nested inside the 12S ribosomal RNA gene, not in the nucleus. The first report came in 2015 in Cell Metabolism, from a group at the University of Southern California that included Changhan Lee and Pinchas Cohen. Of all mitochondrial-derived peptides, only humanin was known earlier.

Where it comes from is the whole attraction. For decades mitochondria were pictured as engines obeying instructions sent down from the nucleus. Here was early evidence that the organelle talks back, releasing a hormone-like signal of its own, and because the sequence is short and clearly defined, chemists can make it easily and labs can work with it.

The Mechanism, From Folate Cycle to AMPK

Skeletal muscle emerged as the principal target in the original 2015 work. Within the cell, MOTS-c blocks the folate cycle along with the de novo purine synthesis that depends on it. The knock-on effect is a pile-up of AICAR, which in turn activates AMPK (AMP-activated protein kinase), the enzyme cells use to detect an energy shortfall. With AMPK switched on, glucose uptake rises and fatty acid use climbs, so MOTS-c lands on the very pathway that a great deal of exercise and metformin research converges on.

Kim and co-workers took this further in a 2018 Cell Metabolism paper. When cells were put under metabolic strain, for instance by limiting glucose, the peptide relocated to the nucleus, a move that needed AMPK, and started controlling nuclear genes, among them NRF2-controlled antioxidant-response genes. A mitochondrial product reaching in to tune nuclear gene expression is what really caught the field's attention.

Animal Findings Behind the MOTS-c Benefits Claims

Strip back the popular claims and two rodent papers carry almost all of the weight.

  • Lee et al., Cell Metabolism, 2015. Animals given MOTS-c did not develop the obesity and insulin resistance a high-fat diet produced in controls, and the age-related insulin resistance seen in muscle was reversed.
  • Reynolds et al., Nature Communications, 2021. Mice aged 2 months, 12 months and 22 months all performed better after treatment, covering young, middle-aged and old animals. Starting intermittent treatment as late as 23.5 months still lifted physical capacity and healthspan markers. The authors also showed that exercise pushes MOTS-c up in human skeletal muscle and in blood.

That human exercise result is where the exercise mimetic tag originated. In mice the description holds up reasonably well. In people it remains unproven that supplying MOTS-c recreates the effects of exercise, and most of the hype around the peptide lives in the space between those two ideas.

CB4211 and the First Human Trials

Just one compound built on MOTS-c has completed a human trial, and it was CB4211, a CohBar analogue tweaked to behave better as a drug than the natural sequence. The trial (ClinicalTrials.gov NCT03998514) had a phase 1a and a phase 1b arm. In the 1b arm, CB4211 or a placebo went to 20 people with obesity and nonalcoholic fatty liver disease once a day under the skin for four weeks. According to CohBar's 2021 report, there were no serious adverse events and tolerability was good. ALT dropped by 25 percent and AST by 17 percent against placebo, glucose came down, and body weight trended lower. All of those readouts were exploratory, the cohort was tiny, the run was short and the molecule was not native MOTS-c.

In 2026 the natural peptide finally reached a clinic of its own. Registered as NCT07505745 and funded by Hudson Biotech, this phase 2a trial opened recruitment in China in February 2026, aiming to randomise around 120 adults who have prediabetes along with overweight or obesity. Participants receive MOTS-c or placebo for 12 weeks, and the primary outcomes are insulin sensitivity, measured with the Matsuda index, and treatment-emergent adverse events. As of this writing, nothing has been posted.

Side Effects and Before and After Claims, Read With Caution

Lists of MOTS-c side effects you see online are guesses, because nobody has published human safety data on the native peptide. A few points are firm. CB4211 produced no serious adverse events during its short trial, and none of the mouse papers reported toxicity. Because its action runs through AMPK and the handling of glucose, any well-built study would put blood sugar at the top of its monitoring list. Reactions at an injection site are common to injected peptides in general. The Hudson Biotech study will be the first to capture adverse events for MOTS-c itself.

Before and after posts deserve the same scepticism. There is no published human study with before and after body composition or performance results for MOTS-c. A progress photo has no comparison group, no proof of what was in the vial and, in most cases, a handful of other compounds running at the same time. We rate MOTS-c as one of the more fascinating peptides a lab can buy, and that is the reason it merits controlled work with confirmed material instead of a sales pitch built on transformation shots.

Handling MOTS-c at the Bench

Three fills are on the shelf at AminoLab, 10, 20 and 40 mg, and the largest is the practical pick for longer protocols. Like most lyophilised peptides it keeps best frozen or in the fridge, protected from light. Full details sit in the peptide storage guide, and the MOTS-c reconstitution calculator handles concentration sums.

For mitochondrial models, common partners are NAD+ for redox and sirtuin work and SS-31, the cardiolipin-targeting peptide. A non-peptide option, SLU-PP-332, reaches exercise signalling by another route, acting on the estrogen-related receptors, and our SLU-PP-332 explainer covers it. All of these sit together in the mitochondrial research range.

Every product mentioned is sold to adults 18 and over for laboratory research only. None is for human or veterinary use, and this page gives no dosing advice.

Order MOTS-c in Australia for Mitochondrial Studies

Every study described here used a synthetic 16 amino acid peptide in measured amounts, and that same compound is what ships from our shelves. Order MOTS-c online as 10mg, 20mg or 40mg vials, and read the lot certificate before checkout. Add bacteriostatic water to the cart, or browse the complete mitochondrial peptides collection. AminoLab ships its MOTS-c from Australian stock straight to your lab door.

Frequently Asked Questions

What exactly is MOTS-c?

A sixteen-residue peptide, MRWQEMGYIFYPRKLR, whose gene sits in mitochondrial DNA within the 12S rRNA region. The 2015 discovery paper by Lee and colleagues appeared in Cell Metabolism in 2015. Its main site of action is skeletal muscle, where it switches on AMPK by interfering with the folate cycle, which is why metabolic regulation is its main research theme.

Are there proven MOTS-c benefits in humans?

Not yet. Mice are the source of every reported gain, from better exercise capacity to protection against diet-induced weight gain and insulin resistance. In humans, the analogue CB4211 reduced liver enzymes over four weeks in 20 participants, while the native peptide entered a phase 2a study in 2026.

What side effects of MOTS-c are known?

No human safety data for native MOTS-c have been published. Its analogue CB4211 caused no serious adverse events across four weeks, and the mouse work reported no toxicity. As MOTS-c influences glucose handling via AMPK, shifts in blood glucose are the chief theoretical issue a study would watch.

Do any MOTS-c before and after results exist?

Not from any controlled source, because no human study has reported such figures yet. Mice ran better on the treadmill and gained less weight on high-fat food, but online photos have no controls, no verified product and no dose records, so they tell you nothing reliable.

How does CB4211 differ from MOTS-c?

CB4211 is a modified analogue that CohBar created from MOTS-c, and it was the compound tested in the only completed human trial. Its results cannot simply be transferred to native MOTS-c, which is being evaluated on its own in the phase 2a trial NCT07505745.

Popular Research Peptides

BPC-157

10 mg vial, 60 capsules

From $69

GHK-Cu

50 mg vial, 100 mg vial

From $49

Bacteriostatic Water

3 mL, 3 mL + 1 syringe, 10 mL, 10 mL + 1 syringe, 30 mL, 30 mL + 1 syringe

From $9
Certificate of analysisEvery research peptide comes with the certificate for its lot, listed in the COA library.
Tested identity and purityIdentity confirmed by mass spectrometry and purity measured by HPLC on every batch.
Australian stockOrders pack and ship from Australia with tracked Australia Post delivery. See delivery information.
Adults 18+ onlySold for laboratory research use only, under our research use policy.

Research use onlyAminoLab supplies research compounds for laboratory and in-vitro use, not for human or animal consumption. By continuing you confirm you are 18 or older and buying for research.

Leave